- Home
- RNTX vs DALN Comparison
RNTX vs DALN Comparison
Compare RNTX & DALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- DALN
- Stock Information
- Founded
- RNTX 2001
- DALN 1954
- Country
- RNTX United States
- DALN United States
- Employees
- RNTX N/A
- DALN N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- DALN Newspapers/Magazines
- Sector
- RNTX Health Care
- DALN Consumer Discretionary
- Exchange
- RNTX Nasdaq
- DALN Nasdaq
- Market Cap
- RNTX 40.3M
- DALN 38.1M
- IPO Year
- RNTX N/A
- DALN 2008
- Fundamental
- Price
- RNTX $1.56
- DALN $4.37
- Analyst Decision
- RNTX
- DALN
- Analyst Count
- RNTX 0
- DALN 0
- Target Price
- RNTX N/A
- DALN N/A
- AVG Volume (30 Days)
- RNTX 33.6K
- DALN 15.3K
- Earning Date
- RNTX 08-13-2025
- DALN 07-29-2025
- Dividend Yield
- RNTX N/A
- DALN N/A
- EPS Growth
- RNTX N/A
- DALN N/A
- EPS
- RNTX N/A
- DALN 5.55
- Revenue
- RNTX N/A
- DALN $123,414,000.00
- Revenue This Year
- RNTX N/A
- DALN N/A
- Revenue Next Year
- RNTX N/A
- DALN N/A
- P/E Ratio
- RNTX N/A
- DALN $0.75
- Revenue Growth
- RNTX N/A
- DALN N/A
- 52 Week Low
- RNTX $1.35
- DALN $2.98
- 52 Week High
- RNTX $4.40
- DALN $7.86
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- DALN 39.58
- Support Level
- RNTX N/A
- DALN $3.82
- Resistance Level
- RNTX N/A
- DALN $4.45
- Average True Range (ATR)
- RNTX 0.00
- DALN 0.24
- MACD
- RNTX 0.00
- DALN 0.00
- Stochastic Oscillator
- RNTX 0.00
- DALN 37.80
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.